Ability Pharmaceuticals, SL announced today that Carles Domenech, PhD, Chief Executive Officer and co-Founder, will be presenting at the Biotech Showcase Conference on Tuesday, January, 8, 2013 at the Parc 55 Wyndham in San Francisco, California (USA). The conference takes place during the course of JP Morgan Healthcare conference, one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Dr. Domènech will present a company overview and will pursuit Ability Pharmaceuticals’s ongoing contacts with the industry and investors.

About Ability Pharmaceuticals
 
Ability Pharmaceuticals is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona and a planned US development office in Boston, Massachusetts (USA) in 2013.
 
Ability Pharmaceuticals develops highly differentiated innovative cancer drugs, with a novel mechanism of action, called Lipid Analog Therapeutics. The company has two drug candidates in development: ABTL0812, which is completing preclinical development, with planned phase Ib clinical trials in lung cancer and pancreatic cancer starting in spring 2013; and ABTL1014, expected to start preclinical development in 1Q 2013.